Skip to main
PCSA
PCSA logo

Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target

Processa Pharmaceuticals (PCSA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Processa Pharmaceuticals Inc. has narrowed its full-year 2026 net loss per share estimate to $0.15 from $0.20, indicating improved financial projections due to an increase in the outstanding share count. The company anticipates that positive interim data from the NGC-Cap mid-stage trial could serve as a significant value inflection point, potentially enhancing investor confidence. Furthermore, Processa's recent strategic investment and exploration of corporate cryptocurrency treasury strategies highlight its commitment to innovative financial management and growth objectives, reinforcing a positive outlook on its stock.

Bears say

Processa Pharmaceuticals is projected to incur a significant net loss of $0.43 per share for the full year 2025, reflecting ongoing financial challenges. In addition, the company faces various operational risks, including potential delays in regulatory approvals, intense competitive pressures that could hinder market penetration and pricing, and the possibility of dilution in the near to medium term. Furthermore, the company's recent net loss of $0.25 per share aligns closely with forecasts, indicating that the financial outlook remains under strain amid these uncertainties.

Processa Pharmaceuticals (PCSA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Processa Pharmaceuticals (PCSA) Forecast

Analysts have given Processa Pharmaceuticals (PCSA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Processa Pharmaceuticals (PCSA) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Processa Pharmaceuticals (PCSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.